X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs STERLING BIOTECH - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD STERLING BIOTECH ALEMBIC LTD/
STERLING BIOTECH
 
P/E (TTM) x 51.3 -0.4 - View Chart
P/BV x 2.2 0.0 15,410.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ALEMBIC LTD   STERLING BIOTECH
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
STERLING BIOTECH
Dec-13
ALEMBIC LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs7211 685.7%   
Low Rs343 997.1%   
Sales per share (Unadj.) Rs4.726.8 17.5%  
Earnings per share (Unadj.) Rs6.1-15.0 -40.8%  
Cash flow per share (Unadj.) Rs6.2-5.5 -114.3%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.754.9 74.1%  
Shares outstanding (eoy) m267.03267.87 99.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 4,344.8%   
Avg P/E ratio x8.7-0.5 -1,867.0%  
P/CF ratio (eoy) x8.5-1.3 -666.4%  
Price / Book Value ratio x1.30.1 1,028.3%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1391,862 759.5%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m207547 37.9%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m1,2557,181 17.5%  
Other income Rs m37043 869.0%   
Total revenues Rs m1,6257,223 22.5%   
Gross profit Rs m111947 11.7%  
Depreciation Rs m382,543 1.5%   
Interest Rs m24,377 0.0%   
Profit before tax Rs m442-5,931 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24-1,924 -1.2%   
Profit after tax Rs m1,630-4,007 -40.7%  
Gross profit margin %8.913.2 67.1%  
Effective tax rate %5.432.4 16.7%   
Net profit margin %129.8-55.8 -232.7%  
BALANCE SHEET DATA
Current assets Rs m1,86714,335 13.0%   
Current liabilities Rs m59149,809 1.2%   
Net working cap to sales %101.6-494.0 -20.6%  
Current ratio x3.20.3 1,097.4%  
Inventory Days Days94403 23.4%  
Debtors Days Days74171 43.1%  
Net fixed assets Rs m1,79155,432 3.2%   
Share capital Rs m534268 199.4%   
"Free" reserves Rs m10,32413,935 74.1%   
Net worth Rs m10,85814,701 73.9%   
Long term debt Rs m419,478 0.4%   
Total assets Rs m11,59173,988 15.7%  
Interest coverage x260.9-0.4 -73,496.1%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.1 111.6%   
Return on assets %14.10.5 2,810.3%  
Return on equity %15.0-27.3 -55.1%  
Return on capital %15.2-6.4 -236.4%  
Exports to sales %1.525.9 6.0%   
Imports to sales %21.00.2 12,348.4%   
Exports (fob) Rs m191,860 1.0%   
Imports (cif) Rs m26312 2,158.5%   
Fx inflow Rs m191,860 1.0%   
Fx outflow Rs m26425 1,059.9%   
Net fx Rs m-2441,835 -13.3%   
CASH FLOW
From Operations Rs m2361,719 13.7%  
From Investments Rs m-224-3,148 7.1%  
From Financial Activity Rs m-271,426 -1.9%  
Net Cashflow Rs m-15-3 435.3%  

Share Holding

Indian Promoters % 64.0 33.9 188.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 9.7 9.9 98.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 26.1 39.3 66.4%  
Shareholders   54,701 21,482 254.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare ALEMBIC LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Down Over 550 Points(12:30 pm)

Share markets in India are presently trading on a negative note. All sectoral indices are trading in red with stocks in the realty sector, banking sector and capital goods sector.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Dec 10, 2018 02:13 PM

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - STERLING BIOTECH COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS